Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
复制标题
DOI：
10.18632/oncotarget.14729
复制
发表时间：
2017-03-28
期刊：
影响因子：
--
通讯作者：
Su GH
中科院分区：
文献类型：
--
作者：
Cai Y;Dodhia S;Su GH
磷酸肌醇 3 激酶 (PI3K) 信号通路是头颈鳞状细胞癌 (HNSCC) 中最常见的突变通路。有几种针对 HNSCC 的针对 PI3K 信号通路成员的药物正在开发中。在本文中，我们回顾了与 HNSCC 相关的通路中报告的遗传改变、针对该通路各种介质的各种正在开发的药物、临床试验的结果以及 PI3K 通路抑制剂开发中仍然存在的挑战。
The phosphoinositide 3-kinase (PI3K) signaling pathway is the most commonly mutated pathway in head and neck squamous cell carcinoma (HNSCC). There are several drugs targeting members of the PI3K signaling pathway in development for HNSCC. In this article, we review the genetic alterations reported in the pathway pertinent to HNSCC, various agents in development targeting various mediators of the pathway, results from clinical trials, and remaining challenges in the development of PI3K pathway inhibitors.